

Bone Health Plan In Trauma And Orthopaedic Discharge Summaries

Quality Improvement Project

H Perera; A Cannon

Bristol Royal Infirmary

Introduction

In 2022, 293 hip fractures were admitted to the Bristol Royal Infirmary. As recommended by The National Osteoporosis Guideline Group (NOGG) intravenous Zoledronate is the first line treatment option following a hip fracture. We wanted to improve bone health summaries on discharge summaries for the benefit of the General practitioner (GP), Fracture liaison service and patient.

Method



We used our local National Hip Fracture database to identify the patients who had had a fractured hip in September 2023. We then introduced our changes as part of the PDSA cycle. The change was copying and pasting a blank bone health paragraph into every discharge summary on day 1 of the patient's admission to make it easier for the Trauma and Orthopaedic (T&O) junior doctor completing the discharge summary pre discharge. We then used an excel spreadsheet to collect results in September and October 2023.

Conclusion

Despite the intervention, the bone health plans are poorly communicated to the GP and the Fracture Liaison service, which leads to delay in administering bone health medication in a timely manner to prevent a second fracture.

Data Analysis

In September, 28.3% of discharge summaries did not have a bone health plan, compared to 25% in October. Not mentioning of Vitamin D levels in discharge summaries has increased from 57.1% to 59.4%. Mentioning of administration of inpatient zoledronic acid post fracture decreased from 32.1% to 25%.



Demonstration of bone health plan in discharge summaries

Next Steps

Teaching Session with the T&O juniors to find out if they think it's a good idea and discuss why they have not found the current standardised paragraph helpful.

Would be helpful for patients who are prescribed IV Zol for the prescriber to check given and add a quick note on discharge letter 'IV Zoledronic acid given on X date' under new medicines page 3. Could be added by orthogeriatric team or T&O but ideally the prescriber

Response we got from a T & O doctor during a survey

Then we can work together to make a further change (s) and start another PDSA cycle.

References

National Osteoporosis Guideline Group.UK (NOGG),2021